Comparing rilzabrutinib and yonalimab

Hanny Al-Samkari provides an indirect comparison of efficacy, side effects, delivery, and quality-of-life differences between agents.

Play episode from 21:47

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!